1
|
Yanagisawa M, Kurihara H, Kimura S, et al:
A novel potent vasoconstrictor peptide produced by vascular
endothelial cells. Nature. 332:411–415. 1988.
|
2
|
Inoue A, Yanagisawa M, Kimura S, et al:
The human endothelin family: three structurally and
pharmacologically distinct isopeptides predicted by three separate
genes. Proc Natl Acad Sci USA. 86:2863–2867. 1989.
|
3
|
Davenport AP: International union of
pharmacology. XXIX. Update on endothelin receptor nomenclature.
Pharmacol Rev. 54:219–226. 2002.
|
4
|
Kusserow H and Unger T: Vasoacitive
peptides, their receptors and drug development. Basic Clin
Pharmacol Toxicol. 94:5–12. 2004.
|
5
|
Ahmed SI, Thompson J, Coulson JM and Woll
PJ: Studies on the expression of endothelin, its receptor subtypes,
and converting enzymes in lung cancer and in human bronchial
epithelium. Am J Respir Cell Mol Biol. 22:422–431. 2000.
|
6
|
Asham E, Shankar A, Loizidou M, et al:
Increased endothelin-1 in colorectal cancer and reduction of tumor
growth by ET(A) receptor antagonism. Br J Cancer. 85:1759–1763.
2001.
|
7
|
Zhang Y, Tang L, Su M, et al: Expression
of endothelines and their receptors in nonmelanoma skin cancers. J
Cutan Med Surg. 10:269–276. 2006.
|
8
|
Spinella F, Rosano L, DiCastro V, Natali
PG and Bagnato A: Endothelin-1 induces vascular endothelial growth
factor by increasing hypoxia-inducible factor-1 alpha in ovarian
carcinoma cells. J Biol Chem. 277:27850–27855. 2002.
|
9
|
Wulfing P, Kersting C, Tio J, et al:
Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression
is correlated with vascular endothelial growth factor expression
and angiogenesis in breast cancer. Clin Cancer Res. 10:2393–2400.
2004.
|
10
|
Boldrin L, Gisfredi S, Ursino S, et al:
Expression of endothelin-1 is related to poor prognosis in
non-small cell lung carcinoma. Eur J Cancer. 41:2828–2835.
2005.
|
11
|
Kandalaft LE, Facciabene A, Buckanovich RJ
and Coukos G: Endothelin B receptor, a new target in cancer immune
therapy. Clin Cancer Res. 15:4521–4528. 2009.
|
12
|
Goepfert H: Squamous cell carcinoma of the
head and neck: past progress and future promise. CA Cancer J Clin.
48:195–198. 1998.
|
13
|
Okura M, Hiranuma T, Adachi T, et al:
Induction chemotherapy is associated with an increase in the
incidence of locoregional recurrence in patients with carcinoma of
the oral cavity: results from a single institution. Cancer.
82:804–815. 1998.
|
14
|
Prince S and Bailey BM: Squamous carcinoma
of the tongue: review. Br J Oral Maxillofac Surg. 37:164–174.
1999.
|
15
|
Masuda T, Wada K, Nakajima A, et al:
Critical role of peroxisome proliferator-activated receptor γ on
anoikis and invasion of squamous cell carcinomas. Clin Cancer Res.
11:4012–4021. 2005.
|
16
|
Takahashi H, Fujita K, Fujisawa T, et al:
Inhibition of peroxisome proliferator-activated receptor gamma
activity in esophageal carcinoma cells results in a drastic
decrease of invasive properties. Cancer Sci. 97:854–860. 2006.
|
17
|
Ishida H, Wada K, Masuda T, et al:
Critical role of estrogen receptor on anoikis and invasion of
squamous cell carcinoma. Cancer Sci. 98:636–643. 2007.
|
18
|
Nagata M, Wada K, Nakajima A, et al: Role
of myeloid cell leukemia-1 on cell growth of squamous cell
carcinoma. J Pharmacol Sci. 110:344–353. 2009.
|
19
|
Kusayama M, Wada K, Nagata M, et al:
Critical role of aquaporin 3 on growth of human esophageal and oral
squamous cell carcinoma. Cancer Sci. 102:1128–1136. 2011.
|
20
|
Chen HC, Appeddu PA, Parsons JT,
Hildebrand JD, Schaller MD and Guan JL: Interaction of focal
adhesion kinase with cytoskeletal protein talin. J Biol Chem.
270:16995–16999. 1995.
|
21
|
Sieg DJ, Hauck CR, Ilic D, et al: FAK
integrates growth-factor and integrin signals to promote cell
migration. Nat Cell Biol. 2:249–256. 2000.
|
22
|
Zhang Z, Vuori K, Reed JC and Ruoslahti E:
The alpha 5 beta 1 integrin supports survival of cells on
fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci
USA. 92:6161–6165. 1995.
|
23
|
Yamada KM and Geiger B: Molecular
interactions in cell adhesion complexes. Curr Opin Cell Biol.
9:76–85. 1997.
|
24
|
Hoffman RR, Yurgel LS and Campos MM:
Endothelins and their receptors as biological markers for oral
cancer. Oral Oncol. 46:644–647. 2010.
|
25
|
Hoffman RR, Yurgel LS and Campos MM:
Evaluation of salivary endothelin-1 levels in oral squamous cell
carcinoma and oral leukoplakia. Regulatory Peptide. 166:55–58.
2011.
|
26
|
Awano S, Dawson LA, Hunter AR, Turner AJ
and Usmani BA: Endothelin system in oral squamous carcinoma cells:
Specific siRNA targeting of ECE-1 blocks cell proliferation. Int J
Cancer. 118:1645–1652. 2006.
|
27
|
Frish SM and Francis H: Disruption of
epithelial cell-matrix interactions induces apoptosis. J Cell Boil.
124:619–626. 1994.
|
28
|
Bogoyevitch MA, Glennon PE, Andersson MB,
et al: Endothelin-1 and fibroblast growth factors stimulate the
mitogen-activated protein kinase signalling cascade in cardiac
myocytes. J Biol Chem. 269:1110–1119. 1994.
|
29
|
Cramer H, Schmenger K, Heinrich K, et al:
Coupling of endothelin receptors to the ERK/MAP kinase pathway. Eur
J Biochem. 268:5449–5459. 2001.
|
30
|
Meyers M, Hwang A, Wagner MW and Boothman
DA: Role of DNA mismatch repair in apoptotic responses to
therapeutic agents. Environ Mol Mutagen. 44:249–264. 2004.
|
31
|
Psyrri A and Fountzilas G: Advances in the
treatment of locally advanced non-nasopharyngeal squamous cell
carcinoma of the head and neck region. Med Oncol. 23:1–15.
2006.
|